InnoCare announces priority review of Orelabrutinib for the treatment of R/R MZL by NMPA
Orelabrutinib is a highly selective BTK inhibitor developed by InnoCare for the treatment of cancers and autoimmune diseases.
Orelabrutinib is a highly selective BTK inhibitor developed by InnoCare for the treatment of cancers and autoimmune diseases.
Phase 2 study to assess efficacy and safety of once daily linperlisib in patients with advanced peripheral T/NK cell lymphoma
Subject Expert Committee(SEC) of Central Drugs Standard Control Organization (CDSCO)
COVID-19 Vaccine (DS-5670) in Unvaccinated Individuals in Japan
The Phase IV DREAM-CKD trial will enrol 1004 CKD patients in India, including 502 dialysis dependent, 502 dialysis independent CKD patients with anemia.
The MOU provides for assistance in the form of efficient working Capital Management, development and commercialisation of new products, logistic supply chain management support etc.
This industry-academia collaboration will provide students with an opportunity to participate in research activities with multiple international universities and scientists
Celanese to conduct research, prototype development and characterization of a refillable contraceptive technology with award from the Bill & Melinda Gates Foundation
75 inter-disciplinary, multi-institutional grants would be supported for high-risk, ambitious research ideas, milestones-driven collaborative research in all domain areas of the biotech sector
Subscribe To Our Newsletter & Stay Updated